Background

A limitation of viral‑mediated gene therapy for neurological diseases is the necessity for a focal injection of virus with limited ability to transduce cells across the entire brain away from the focal point of injection. What is needed is a way for the viral expressed therapeutic protein produced by transduced cells to disseminate away from the injection site to effect cells across the entire span of the brain.

Technology Overview

This technology is a gene therapy vector and method to deliver a therapeutic protein to the brain of neurological disease patients (i.e. Alzheimer’s patients) which in our experimental models has been demonstrated to virtually eliminate beta-amyloid. The main advantage of this vector, is that it is adenovirus-associated virus based,